Oxemia - Let freedom flow
For healthcare professionals

Dosing and administration

Use the information below to select the appropriate dosing
for your patient.

This summary does not replace the approved Prescribing Information (PI)
or clinical judgement. Always refer to the full PI before prescribing.

Anatomical illustration of human kidneys
1

Select the care setting first

Not on dialysis
(NDD-CKD)For adults with CKD anaemia not receiving dialysis.On dialysis
(DD-CKD)For adults with CKD anaemia receiving dialysis.
2

Starting dose

Not on dialysis (NDD-CKD)

Tablet

100 mg

three times weekly

Maximum dose150 mg three times weekly

On dialysis (DD-CKD)

New patient (not on ESA)

100 mg

three times weekly

Converting patient (on ESA)

Use PI-based conversion table (100 / 125 / 150 mg three times weekly) according to prior ESA dose.

3

Administration schedule

  • Calendar
    Doses two days apart, not four days apart.Examples: Monday / Wednesday / Fridayor Tuesday / Thursday / Saturday.
  • Patient in a dialysis chair
    For patients on dialysis:Take dose after completion of the dialysis session.
  • Cutlery
    Take OXEMIA:No food 1 hour before and 2 hours after the dose.
4

Monitor and adjust (Review change in Hb every 4 weeks)

Haemoglobin (Hb)
level (g/dL)		Change in Hb over 4 weeks
Increase ≥ 1.0 g/dLIncrease 0.5 to < 1.0 g/dLChange within ± 0.5 g/dLDecrease > 0.5 g/dL
Hb < 10Increase dose by25 mgMaintain current doseIncrease dose by25 mgIncrease dose by25 mg
Hb 10 to < 12Maintain current doseMaintain current doseMaintain current doseIncrease dose by25 mg
Hb ≥ 12STOP OXEMIA for 14 days.When Hb < 11.5 g/dL,
restart at one dose lower.		Maintain current doseReduce dose by25 mgReduce dose by25 mg

Do not increase the dose above 150 mg three times weekly.

5

Conversion table for dialysis patients on ESA

Prior ESAPrior doseDesidustat dose
(three times weekly)
Epoetin< 8,000 IU/week100 mg
8,000 to 16,000 IU/week125 mg
> 16,000 IU/week150 mg
Darbepoetin< 40 µg/week100 mg
40 to 80 µg/week125 mg
> 80 µg/week150 mg
Methoxy polyethylene glycol-epoetin beta< 120 µg/month100 mg
120 to 200 µg/month125 mg
> 200 µg/month150 mg

Use the above table to select the starting dose for dialysis patients converting from an ESA. Subsequently, adjust the dose based on Hb as per the dose adjustment table (Section 4). Refer to the PI for full details.

6

Before prescribing

  • Confirm indication: Anaemia due to CKD (on dialysis and not on dialysis).
  • Ferritin level:>200 ng/mL.
  • Transferrin saturation level:>20%.
  • Folate level: Within the normal range.
  • Vitamin B12 level: Within the normal range.
7

Practical references

  • Heart rate line
    Strengths100 mg tablets(for oral use)See PI
  • Clipboard
    CompositionEach film-coated tabletcontains 100 mgdesidustat.See PI
  • Thermometer
    StorageStore below 30°C.Protect from moisture.See PI
  • Download
    Full PIFor complete information onindication, dosing, safety,and more.Download PI
  • Headset
    Medical informationFor scientific enquiriesor medical information.Contact
8

Related evidence

Non-dialysis (NDD-CKD)

DREAM-ND Phase III study

Desidustat 100 mg three times weekly (titrated up to 150 mg) vs darbepoetin alfa in non-dialysis CKD anaemia.

View DREAM-ND evidence
Dialysis (DD-CKD)

DREAM-D Phase III study

Desidustat (starting 100/125/150 mg three times weekly per conversion) vs epoetin alfa in dialysis-dependent CKD anaemia.

View DREAM-D evidence
Important

This information is a summary. Always refer to the approved Prescribing Information for complete details.

Open full PI